Phase 2 RCT in 271 patients with metastatic TNBC benefiting from first-line pembrolizumab plus chemotherapy: switching to pembrolizumab plus olaparib did not improve median PFS (5.5 vs 5.6 months; HR 0.98) or OS (25.1 vs 23.4) vs continued chemotherapy (primary endpoint not met).
RCTn = 271
Rugo et al. KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy